PorTal Access, Inc. Completes FDA 510(k) Submission for Flexi-Port™
PorTal Access, Inc. has completed its FDA 510(k) submission for the Flexi-Port™, marking a significant milestone towards the commercialization of this next-generation vascular access device designed for oncology. The launch is anticipated in mid-summer 2026. The Flexi-Port™ offers a novel design aimed at improving the patient experience and clinician workflow.
Mid-Summer Launch Anticipated for Next-Generation Oncology Vascular Access Platform MIAMI, May 18, 2026 /PRNewswire/ — PorTal Access, Inc., a medical device company pioneering next-generation vascular access solutions for oncology, today announced the successful completion of its U.S….